Rilpivirine

Drugbox
IUPAC_name = 4-{ [4-({4- [("E")-2-cyanoethenyl] -2,6-dimethylphenyl}
amino)pyrimidin-2-yl] amino}benzonitrile

---

CAS_number = 500287-72-9
ATC_prefix =
ATC_suffix =
PubChem = 6451164
DrugBank =
C=22|H=18|N=6
molecular_weight = 366.42 g/mol
bioavailability =
protein_bound =
metabolism =
elimination_half-life = 38 hours
excretion =
pregnancy_AU =
pregnancy_US =
pregnancy_category=
legal_AU =
legal_CA =
legal_UK =
legal_US =
legal_status =
routes_of_administration = Oral

Rilpivirine (TMC278) is an investigational new drug, developed by Tibotec, for the treatment of HIV infection.cite journal |author=Stellbrink HJ |title=Antiviral drugs in the treatment of AIDS: what is in the pipeline ? |journal=Eur. J. Med. Res. |volume=12 |issue=9 |pages=483–95 |year=2007 |pmid=17933730 |doi=] It is a second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) with higher potency, longer half-life and reduced side-effect profile compared with older NNRTIs, such as efavirenz. [cite journal |author=Goebel F, Yakovlev A, Pozniak AL, Vinogradova E, Boogaerts G, Hoetelmans R, de Béthune MP, Peeters M, Woodfall B |title=Short-term antiviral activity of TMC278--a novel NNRTI--in treatment-naive HIV-1-infected subjects |journal=AIDS |volume=20 |issue=13 |pages=1721–6 |year=2006 |pmid=16931936 |doi=10.1097/01.aids.0000242818.65215.bd |url=http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?an=00002030-200608220-00005] [Pozniak A, Morales-Ramirez J, Mohap L et al. [http://www.retroconference.org/2007/Abstracts/30659.htm 48-Week Primary Analysis of Trial TMC278-C204: TMC278 Demonstrates Potent and Sustained Efficacy in ART-naïve Patients.] Oral abstract 144LB.] It entered phase III clinical trials on April 2008, with an estimated study completion date on August, 2010. [ClinicalTrials.gov [http://clinicaltrials.gov/ct2/show/NCT00540449 A Clinical Trial in Treatment naïve HIV-1 Patients Comparing TMC278 to Efavirenz in Combination With Tenofovir + Emtricitabine] ] [ClinicalTrials.gov [http://clinicaltrials.gov/ct2/show/NCT00543725 A Clinical Trial in Treatment naïve HIV-Subjects Patients Comparing TMC278 to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors] ] Like etravirine, a second-generation NNRTI approved in 2008, rilpivirine is a diarylpyrimidine (DAPY).

References